Corebridge Financial Inc. reduced its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 4.7% during ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zentalis Pharmaceuticals (ZNTL – Research ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.

In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biotech company with a market capitalization of $7.27 billion and strong financial health indicators according to InvestingPro data, ...